Testing for serum IgM binding to GM1 ganglioside in clinical practice
| Autor: | A. Pestronk, E. Nobile-Orazio, M. Carpo, G. Scarlato, R. G. Holloway, T. E. Feasby |
|---|---|
| Rok vydání: | 2000 |
| Předmět: | |
| Zdroj: | Neurology. 54:2353-2354 |
| ISSN: | 1526-632X 0028-3878 |
| DOI: | 10.1212/wnl.54.12.2353 |
| Popis: | To the Editor: A recent article by Carpo et al.1 and an associated editorial by Holloway and Feasby2 dealt with a variety of issues regarding serum testing for IgM anti-GM1 antibodies. Although there have been several collaborations across study centers to evaluate such testing,3,4 in which we have always participated, ELISA methods for measuring IgM anti-GM1 antibodies are not standardized. Carpo et al. and many commercial laboratories use methodologies that differ from ours,5,6 and each other, in important aspects. We compared our Co-GM1 ELISA assay methods to the techniques that were outlined by Carpo et al.,1 including their algorithms for serum dilutions, coating of control wells with bovine serum albumin, and determination of sera with antibody levels over background. We simultaneously tested 22 multifocal motor neuropathy (MMN) sera (from our previous study) and 24 disease control sera. ⇓ View this table: Table 1. Methods We have also completed an extensive quality control study of our methods of analysis of IgM binding to Co-GM1 and NP-9 antigen, based on the actual clinical practice of our referral laboratory. Test results of more than 5,000 sera sent for routine analysis to our laboratory, and clinical correlations with our own patients from a subset of these sera, confirm our original data.5 Sensitivity: MMN is a clinical motor neuropathy syndrome, as described in several publications.7-10 Motor conduction block is a focal reduction (>50%) in compound muscle action potential (CMAP) amplitudes in distal nerves at locations other than sites of compression. IgM anti-Co-GM1 antibodies with … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|